Necrosis of the skin and subcutaneous tissues, following inadvertent extravasation of cytotoxic drugs, is a serious and potentially fatal complication of cancer chemotherapy (Lippman et al., 1972) . Although, in experienced hands, such extravasation occurs with less than one i.v. injection in a hundred, more than 5% of patients at risk will suffer a drug-induced soft-tissue injury since each receives multiple injections during a conventional treatment regimen (Barlock et al., 1979) .
Having established a model of soft-tissue injury induced by anti-neoplastic drugs in the guinea pig , a preliminary evaluation was undertaken to assess the prospect of secondary prophylaxis, i.e. the prevention of gross tissue damage by pharmacological intervention after the injurious event. Four agents were selected for study on the basis of putative or anecdotal value (Barr & Sertic, 1981) . No major benefit was derived from this approach, at least as it was employed; but modest diminution in toxicity did follow the use of hydrocortisone.
Indeed, aggressive steroid intervention may be helpful. in clinical practice (Barlock et al., 1979) , although much more effective methods of prevention must be sought.
Following a description of promising results with the use of topical dimethylsulphoxide (DMSO), applied either locally or at a site distant from that harbouring the injurious drug (Desai et al., 1981) , a detailed report of the value of DMSO, alone and in combination with the anti-oxidant alphatocopherol (Vitamin E), was published very recently (Svingen et al., 1982) . In that study, a mixture of DMSO and Vitamin E was moderately efficacious in reducing soft-tissue necrosis induced in rats by the i.d. injection of Adriamycin. Again, a systemic effect of DMSO was suggested. However, in no instance was the injury prevented completely.
The present study was undertaken to examine the roles of DMSO and Vitamin E in the secondary prevention of soft tissue injury following the i. employed as intervention agents. The latter was dissolved in the former (DMSO) to achieve solutions of 10 and 50g per 100ml. Isotonic saline was used as the control. One ml volumes of these solutions were applied topically to the skin with cotton-tipped applicators immediately after the injection of Adriamycin.
Each animal was examined every day and any lesions observed were scored according to a simple rating described previously Barr & Sertic, 1981) and given in detail in Table I . At Although lesions induced by all doses of Adriamycin evolved more slowly with the topical application of increasing concentrations of alpha tocopherol succinate in DMSO (zero, 10 and 50% in protocols 1, 2 and 3 respectively), lesions with doses A and B were fully developed (4+) in all animals by Day 9. The maximum intensity of soft tissue injury caused by dose C was delayed to Day 12 and it was inversely related to the concentration of alpha tocopherol succinate. A similar, albeit less pronounced effect was seen after dose D, although no lesion was observed in any animal receiving this dose within one week of injection. Lesions following doses C and D resolved completely in all animals and the rate was related directly to the concentration of alpha tocopherol succinate used for intervention. Within 3 weeks the lesions produced by dose B showed early healing only in those animals in which intervention by protocols 2 and 3 was undertaken. By 6 weeks all lesions revealed evidence of healing, although many which had been 4+ in intensity exhibited prominent scar formation.
Following inadvertent extravasation in clinical practice, Adriamycin can be detected in the skin for several months (Garnick et al., 1981) . The resulting manifestations of soft-tissue injury may be due to enzymatic reduction of the drug to free radicals (Powis & Appel, 1980) which can form cytotoxic hydroxyl radicals in the presence of molecular oxygen (Fridovich, 1976) . These free and hydroxyl radicals may be susceptible to scavenging by alpha tocopherol and dimethyl sulphoxide respectively (Tappel, 1962; Cederbaum et al., 1977) . DMSO also facilitates skin penetration (Kligman, 1965) and may disperse Adriamycin from within the skin.
Considerations such as these led Svingen et al. (1981) to investigate the roles of DMSO and alpha tocopherol in the secondary prevention of ulceration following i.d. injection of Adriamycin in rats. Their studies demonstrated that the topical application of 10% alpha tocopherol succinate in DMSO at the injection site reduced the mean ulcer diameter.
In our experiments using a guinea pig model, the doses of Adriamycin used were critical. By the i.d. route, 0.01 mg was the minumum amount of the drug which evoked consistent early lesions; a figure identical to that obtained by Rudolph et al. (1979) . For animals weighing -250 g, a s.c. dose of 2mg was a satisfactory compromise between early fatal toxicity and lack of local injury. When the drug was given by the i.d. route we confirmed the value of DMSO plus alpha tocopherol succinate in reducing soft tissue injury. Furthermore, this beneficial effect was more evident with the higher concentration of Vitamin E (50%), although it was progressively less with increasing doses of Adriamycin.
As a parallel to clinical circumstances, s.c. injection is a more accurate reflection of inadvertent extravasation since Adriamycin is administered customarily into an established i.v. infusion. Our data on the efficacy of DMSO in 875 preventing soft-tissue injury in most animals following s.c. injection of Adriamycin are thus clinically valid. There was no merit in applying DMSO at a site distant from that at which Adriamycin was injected, as has been suggested by others (Desai et al., 1981) . In any event this manoeuvre has no relevance to clinical practice.
DMSO is virtually non-toxic in humans (Rubin, 1975) , as is alpha tocopherol in less than megadoses (Ayres et al., 1979) . Although pre-treatment with systemic Vitamin E may potentiate Adriamycin-induced myelosuppression in mice (Alberts et al., 1978) , it is unlikely that this will be a factor in the topical use of small amounts during the short-term for the prevention of drug-induced skin necrosis. Therefore we recommend that a solution of 50% alpha tocopherol succinate in DMSO be readily available at all times in locations in which patients are receiving i.v. cytotoxic chemotherapy, especially with Adriamycin, so that it may be applied promptly to any site of suspected extravasation with a view to preventing or at least diminishing the consequent soft tissue injury.
